Prostate cancer is Australia's most commonly diagnosed cancer. One in six men will be diagnosed by the time they turn 85. Cancers are abnormal groups of cells that grow uncontrollably and start invading neighboring sites.
They can also spread to other organs in the body. This is known as metastasis. Treatment of early disease, when cancer is confined to the original site, is focused on that single area, most often with surgery or radiation therapy.
Treatment of advanced disease, when it has spread, often relies on treatments that can travel all around the body, such as chemotherapy or immunotherapy. A more advanced form of radiation therapy, called stereotactic ablative radiotherapy, may be able to treat both early and advanced cancers. So how does it work? And how does it compare to existing therapies? It delivers a higher dose to a smaller target Stereotactic radiotherapy uses high doses of radiation to target and kill cancer cells.
It uses newer machines that can deliver very focused radiation beams. Combined with advances in imaging and radiation planning software, this allows clinicians to "track" and target cancers. This results in such high precision—with a targeting accuracy less than 1mm—that cancers can be safely treated with minimal risk of damaging surrounding healthy organs.
Having a higher dose means radiotherapy can be delivered in fewer treatments (one to five sessions over one to two weeks) where it previously would have been divided into many small doses.
